Stock listing

NASDAQ:CMMB Chemomab Therapeutics Ltd. Stock

Follow Chemomab Therapeutics Ltd. into a list and get an email when it puts out news.

Share price · NASDAQ:CMMB

$1.19 USD +0.05 (+4.4%)

Close on Nov 20, 2026

Past year -51.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.15 – $1.33 USDNov 20, 2026
Volume
70,813 sharesNov 20, 2026
Market cap
$9.58M USDAt the close on Nov 20, 2026 · price × 8.05M shares outstanding
52-week range
$0.92 – $2.99 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$194,866 USDMedian day 72,450 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Chemomab Therapeutics Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CMMB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.19+0.05+4.4%$1.17$1.33$1.14870,813
$1.14-0.41-26.5%$1.54$1.60$1.1091,300
$1.55-0.09-5.5%$1.70$1.70$1.4537,800
$1.64+0.02+1.2%$1.65$1.70$1.56166,100
$1.62+0.09+5.9%$1.55$1.72$1.5072,400
$1.53+0.13+9.3%$1.455$1.60$1.39585,500
$1.40+0.05+3.7%$1.35$1.49$1.3576,500
$1.35+0.005+0.4%$1.33$1.42$1.27558,800
$1.345+0.035+2.7%$1.36$1.405$1.21105,000
$1.31-0.01-0.8%$1.34$1.42$1.3134,300
$1.32+0.07+5.6%$1.27$1.38$1.2559,300
$1.25+0.02+1.6%$1.18$1.30$1.18142,100
$1.23+0.05+4.2%$1.267$1.30$1.1428,700
$1.180.000.0%$1.33$1.33$1.1638,900
$1.18+0.02+1.7%$1.22$1.23$1.1576,400
$1.16+0.07+6.4%$1.14$1.16$1.01224,500
$1.09-0.01-0.9%$1.101$1.19$1.0941,000
$1.10+0.05+4.8%$1.05$1.155$1.0421,800
$1.05+0.05+5.0%$1.045$1.06$1.018,900
$1.00-0.03-2.9%$1.10$1.10$0.9235,200
$1.03-0.05-4.6%$1.10$1.205$1.0125,900
$1.08-0.07-6.1%$1.15$1.24$1.0154,800
$1.15-0.03-2.5%$1.18$1.23$1.1514,800
$1.18+0.01+0.9%$1.24$1.29$1.1764,800
$1.17-0.095-7.5%$1.25$1.26$1.1736,600
$1.265-0.025-1.9%$1.27$1.35$1.2579,100
$1.290.000.0%$1.29$1.355$1.2521,500
$1.29+0.05+4.0%$1.26$1.345$1.2625,800
$1.24-0.15-10.8%$1.37$1.41$1.2449,800
$1.39+0.01+0.7%$1.38$1.46$1.3817,200
$1.38-0.01-0.7%$1.39$1.47$1.3712,200
$1.39+0.02+1.5%$1.40$1.44$1.3620,600
$1.37-0.03-2.1%$1.38$1.399$1.3610,000
$1.40-0.01-0.7%$1.57$1.57$1.3825,200
$1.41-0.02-1.4%$1.43$1.49$1.3955,300
$1.43+0.13+10.0%$1.30$1.435$1.3041,900
$1.30+0.11+9.2%$1.25$1.40$1.25195,400
$1.19-0.42-26.1%$1.62$1.665$1.051677,100
$1.61-0.03-1.8%$1.59$1.77$1.50437,800
$1.64-0.52-24.1%$2.20$2.22$1.61349,800
$2.16-0.04-1.8%$2.20$2.262$2.1063,200
$2.20-0.08-3.5%$2.25$2.279$2.1697,200
$2.28-0.10-4.2%$2.41$2.41$2.159133,500
$2.38-0.10-4.0%$2.46$2.627$2.36133,000
$2.48-0.13-5.0%$2.65$2.70$2.4682,300
$2.61-0.19-6.8%$2.73$2.88$2.57175,800
$2.80+0.15+5.7%$2.74$2.80$2.56130,700
$2.65+0.18+7.3%$2.55$2.74$2.51115,100
$2.47+0.02+0.8%$2.46$2.559$2.4150,900
$2.45-0.13-5.0%$2.575$2.58$2.377104,200
$2.58-0.02-0.8%$2.66$2.76$2.56100,700
$2.60-0.09-3.3%$2.665$2.70$2.5923,800
$2.69-0.06-2.2%$2.75$2.80$2.5976,600
$2.75+0.04+1.5%$2.67$2.879$2.6695,900
$2.71-0.12-4.2%$2.90$2.941$2.71118,500
$2.83+0.10+3.7%$2.82$2.94$2.71150,800
$2.730.000.0%$2.73$2.84$2.7141,300
$2.73+0.01+0.4%$2.71$2.89$2.7072,500
$2.72+0.01+0.4%$2.70$2.80$2.6441,600
$2.71-0.01-0.4%$2.73$2.88$2.61105,100
$2.72+0.13+5.0%$2.57$2.99$2.57379,600
$2.59+0.29+12.6%$2.36$2.65$2.32420,500
$2.30+0.13+6.0%$2.12$2.37$2.12139,600
$2.17+0.01+0.5%$2.16$2.27$2.0879,700
$2.16+0.09+4.3%$2.06$2.20$2.04114,200
$2.07-0.02-1.0%$2.06$2.10$1.9583,400

Splits

2 splits since 2021 · NASDAQ:CMMB · every price before a split is adjusted for it

DayRatioWhat
1-for-4Consolidation
1-for-16Consolidation
Ticker
NASDAQ:CMMB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Chemomab Therapeutics Ltd. news

Chemomab Therapeutics Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
2 in the last 12 months · 2 in all · newest Nov 19, 2026 · oldest 2026
Calls
5 calls with a replay · 5 with a transcript · latest May 11, 2023
Decks
16 decks · latest September 2026

Valuation

Price/book 2.6× against a median of 0.6×: the highest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$4.92M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
2.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.04

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Chemomab Therapeutics Ltd. · NASDAQ:CMMBUS$9.58MUS$4.92Mn/an/an/a2.6×n/a0.0×1.04
Ceryvyn Therapeutics Limited · ASX:CYVUS$9.96M−US$9.91M0.1×−14,971×n/a0.5×n/a0.0×n/a
aTyr Pharma, Inc. · NASDAQ:ATYRUS$9.74M−US$28.09Mn/an/an/a0.3×n/a0.3×2.12
Lisata Therapeutics, Inc. · NASDAQ:LSTAUS$9.71M−US$273.0Mn/a−2,730×n/a1.3×n/a0.0×0.71
Purple Biotech Ltd. · TASE:PPBTUS$9.70MUS$3.73Mn/an/an/a0.8×n/a0.0×n/a
Jasper Therapeutics, Inc. · NASDAQ:JSPRUS$9.64M−US$125.6Mn/a−15.7×n/an/an/an/a2.02
Alzinova AB · OMXSTO:ALZUS$9.57MUS$8.34Mn/a17.0×n/a0.6×−484.4%0.0×n/a
Genvor Incorporated · OTC:GNVRUS$9.47MUS$9.27Mn/an/an/an/an/an/a0.44
Poxel SA · EURONEXT:POXELUS$9.27MUS$73.95Mn/an/an/an/an/an/an/a
TScan Therapeutics, Inc. · NASDAQ:TCRXUS$9.27M−US$30.80Mn/a−5.9×n/a0.2×n/a0.9×1.66
Rapid Dose Therapeutics Corp · CSE:DOSEUS$9.13MUS$9.12Mn/a5.1×n/an/a−123.1%n/a0.64
Median of the othersUS$9.60M−US$3.09M0.1×−10.8×0.6×−303.7%0.0×1.19

Forecasts

1 buy · Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.

Price target
5.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.020 · 1 analyst

Team and board

Officers

OfficerRole
Adi MorCo-Founder, Chief Executive Officer and Chief Scientific Officer
Sigal FattalChief Financial Officer
Barbara LindheimConsulting Vice President, Strategic Communications, Investor & Public Relations
Revital ArichaVice President, Translational Science
David WeinerInterim Chief Medical Officer
Jack LawlerChief Development Officer

Board

DirectorRole
Nissim DarvishBoard Chairman
Alan MosesBoard Director
Claude NicaiseBoard Director
Gwen MelincoffBoard Director
Jill QuigleyBoard Director
Neil CohenBoard Director

Events

Results days

QuarterResultsShare move
Q3 2026Nov 19, 2026 · Before open−26.4%
Q2 2026Sep 24, 2026−5.3%
Q1 2026May 14, 2026 · Before open−2.3%
Q3 2025Nov 20, 2025 · Before open−10.0%
Q2 2025Aug 14, 2025 · Before open−6.4%
Q1 2025May 15, 2025 · Before open+6.6%
Q4 2024Mar 5, 2025 · Before open+7.7%
Q3 2024Nov 14, 2024 · Before open0.0%
Q2 2024Aug 21, 2024 · Before open−1.6%
Q1 2024May 9, 2024 · Before open+11.7%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 7, 2024 · Before open+12.7%
Q3 2023Nov 9, 2023 · Before open−6.1%
Q2 2023Aug 14, 2023 · Before open−4.2%
Q1 2023May 11, 2023 · Before open−1.5%
Q4 2022Feb 21, 2023 · Before open+16.8%
Q3 2022Nov 10, 2022 · After close0.0%
Q2 2022Aug 12, 2022 · Before open+7.2%
Q1 2022May 12, 2022 · Before open−1.0%
Q4 2021Mar 9, 2022 · Before open+4.4%
Q3 2021Nov 12, 2021 · Before open+2.9%

Open Events

Decks

DeckKindSlidesDate
Merger or Acquisition (September 2026)Merger or acquisition32 slidesSeptember 2026
Investor Presentation (May 2025)Investor deck49 slidesMay 28, 2025
DDW 2025Conference25 slidesMay 4, 2025
Investor Presentation (February 2025)Investor deck39 slidesFebruary 2025
AASLD 2024Conference19 slidesNovember 2024
Technical Presentation (July 2024)Technical20 slidesJul 25, 2024
Investor Presentation (January 2023)Investor deck35 slidesJan 11, 2023
AASLD 2023Conference15 slides2023
EASL 2022Conference19 slidesJune 2022
Investor Presentation (November 2021)Investor deck27 slidesNov 10, 2021
All 16 decks
DeckKindSlidesDate
Technical Presentation (November 2021)Technical39 slidesNov 3, 2021
Investor Presentation (October 2021)Investor deck26 slidesOct 25, 2021
Investor Presentation (September 2021)Investor deck26 slidesSep 2, 2021
Anchiano Therapeutics — Global Life Sciences Conference March 9-10, 2021Conference21 slidesMar 9, 2021
Anchiano Therapeutics — Merger or Acquisition (January 2021)Merger or acquisition19 slidesJan 11, 2021
Anchiano Therapeutics — Investor Presentation (February 2020)Investor deck28 slidesFeb 4, 2020

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue000000000
Cost of revenue2.33M2.46M4.39M5.14M3.31M80.6K281.0K66.0K51.0K40.6K
Gross profit-70.6K-53.3K-66.8K-57.8K-34.0K-80.6K-281.0K-66.0K-51.0K-40.6K
Research and development5.83M11.3M18.4M17.0M6.33M4.68M13.3M7.51M6.23M2.34M
Selling, general and administrative3.73M3.41M7.08M11.6M6.03M1.29M6.25M5.49M3.27M
Operating income-112.0M-103.0M-25.5M-28.5M-12.4M-11.0M27.1M12.7M-9.39M-4.63M
Depreciation and amortization70.0K53.0K67.0K58.0K34.0K24.0K281.0K66.0K51.4K40.8K
EBITDA-111.9M-102.9M-25.4M-28.5M-12.3M-11.0M27.4M12.7M-9.34M-4.59M
Interest expense353.0K111.1K6.04K4.23M05.00K
Income before tax-8.99M-13.9M-24.2M-28.2M-12.5M5.95M27.1M13.5M-9.56M-4.61M
Income tax000-534.0K000306.0K323.0K136.2K
Net income-8.99M-13.9M-24.2M-27.6M-12.5M-5.95M-27.1M-13.8M-9.81M-4.73M
Earnings per share, basic0.020.040.100.120.060.040.791.09-869.25-69.69
Earnings per share, diluted0.020.040.100.120.060.040.791.09

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents7.56M6.07M9.29M13.5M15.2M11.7M17.6M7.52M1.45M4.56M
Short-term investments2.80M8.20M10.5M26.4M46.0M24.0K
Receivables3.06M263.0K289.0K459.0K179.0K74.0K408.0K3.40M88.0K139.0K
Inventory1-1.04M-1.35M-657.0K-542-77.0K1
Current assets13.4M16.0M20.9M41.7M62.7M11.8M18.2M10.9M1.59M4.87M
Property, plant and equipment176.0K250.0K303.0K367.0K357.0K152.0K158.0K385.0K
Total assets13.8M17.0M22.2M43.1M64.4M12.5M19.8M12.8M2.09M5.65M
Accounts payable485.0K633.0K516.0K1.69M1.34M93.0K25.0K396.0K160.0K106.5K
Current liabilities1.48M3.22M4.84M6.75M2.65M1.32M4.12M2.75M2.70M2.36M
Total debt324.0K392.0K214.0K343.0K607.0K586.0K
Total liabilities1.48M3.43M5.15M6.84M2.89M1.67M4.85M2.96M2.70M2.36M
Shareholders' equity12.3M13.5M17.0M36.2M61.5M10.8M12.4M9.80M-609.0K3.29M
Shares outstanding575.4M377.1M284.1M232.6M228.1M9.27M37.1M15.6M11.3K67.9K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-11.1M-15.4M-23.6M-20.4M-12.4M-5.24M-16.5M-14.2M-8.58M-3.74M
Capital spending-3.00K0-3.00K-68.0K-239.0K-38.0K-95.0K-213.0K-34.3K-76.1K
Free cash flow-11.1M-15.4M-23.6M-20.4M-12.6M-5.28M-16.6M-14.4M-8.62M-3.81M
Cash from investing5.39M2.30M15.9M19.5M-45.2M-62.0K-95.0K-213.0K-34.3K77.9K
Cash from financing7.16M9.87M3.50M-808.0K61.1M4.75M26.6M20.6M5.28M6.06M
Share buybacks00-1.22M0
Change in cash1.42M-3.22M-4.23M-1.65M3.51M-554.0K10.1M6.18M-3.11M2.35M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 19, 2026Current reportSEC
SCHEDULE 13D · Big-stake noticeNov 10, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialNov 10, 2026Meeting noticeSEC
6-K · Report of a foreign issuerNov 3, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveNov 2, 2026Other filingsSEC
DEFM14AOct 30, 2026Meeting noticeSEC
S-4/A · Registration statement, amendedOct 29, 2026Offer documentSEC
6-K · Report of a foreign issuerOct 19, 2026Current reportSEC
S-4/A · Registration statement, amendedOct 19, 2026Offer documentSEC
6-K · Report of a foreign issuerSep 30, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
S-4 · Registration statementSep 25, 2026Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 9, 2026Big-stake noticeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
6-K · Report of a foreign issuerAug 19, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2026Big-stake noticeSEC
DRS · Draft registration statementAug 11, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 10, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeJul 16, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerJul 8, 2026Current reportSEC
3 · Initial statement of ownershipJun 3, 2026Insider tradeSEC
6-K · Report of a foreign issuerJun 2, 2026Current reportSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
6-K · Report of a foreign issuerMay 14, 2026Current reportSEC
6-K · Report of a foreign issuerMay 6, 2026Current reportSEC
6-K · Report of a foreign issuerApr 28, 2026Current reportSEC
3 · Initial statement of ownershipApr 10, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 10, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 10, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 10, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 10, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 10, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
20-F · Annual reportMar 23, 2026Annual reportSEC
6-K · Report of a foreign issuerMar 20, 2026Current reportSEC
6-K · Report of a foreign issuerMar 19, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerNov 21, 2025Current reportSEC
6-K · Report of a foreign issuerAug 22, 2025Current reportSEC
6-K · Report of a foreign issuerAug 14, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 11, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerJul 25, 2025Current reportSEC
424B5 · ProspectusJul 25, 2025Offer documentSEC
6-K · Report of a foreign issuerJul 1, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 23, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerMay 27, 2025Current reportSEC
6-K · Report of a foreign issuerMay 15, 2025Current reportSEC
6-K · Report of a foreign issuerApr 15, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 10, 2025Big-stake noticeSEC
20-F · Annual reportApr 4, 2025Annual reportSEC
6-K · Report of a foreign issuerMar 27, 2025Current reportSEC
6-K · Report of a foreign issuerMar 20, 2025Current reportSEC
6-K · Report of a foreign issuerMar 3, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 19, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveDec 11, 2024Other filingsSEC
POS AM · Amendment to an effective registrationDec 2, 2024Offer documentSEC
SC 13D/A · Big-stake notice, amendedNov 29, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 21, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerNov 18, 2024Current reportSEC
424B5 · ProspectusNov 15, 2024Offer documentSEC
6-K · Report of a foreign issuerNov 14, 2024Current reportSEC
6-K · Report of a foreign issuerOct 11, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedSep 16, 2024Big-stake noticeSEC
144 · Notice of proposed saleSep 12, 2024Other filingsSEC
424B3 · ProspectusSep 9, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 9, 2024Other filingsSEC
CORRESP · Letter to the SECSep 4, 2024Other filingsSEC
UPLOAD · Letter from the SECAug 29, 2024Other filingsSEC
F-3 · Registration statementAug 23, 2024Offer documentSEC
6-K · Report of a foreign issuerAug 21, 2024Current reportSEC
SC 13G · Big-stake noticeAug 20, 2024Big-stake noticeSEC
DAug 9, 2024Other filingsSEC
6-K · Report of a foreign issuerJul 25, 2024Current reportSEC
6-K · Report of a foreign issuerJun 12, 2024Current reportSEC
6-K · Report of a foreign issuerMay 9, 2024Current reportSEC
6-K · Report of a foreign issuerMay 8, 2024Current reportSEC
6-K · Report of a foreign issuerMay 3, 2024Current reportSEC
20-F · Annual reportMar 28, 2024Annual reportSEC
SC 13D/A · Big-stake notice, amendedMar 11, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerMar 7, 2024Current reportSEC
6-K · Report of a foreign issuerJan 3, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 15, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerNov 9, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveNov 6, 2023Other filingsSEC
CORRESP · Letter to the SECNov 1, 2023Other filingsSEC
F-3/A · Registration statement, amendedOct 30, 2023Offer documentSEC
F-3 · Registration statementOct 16, 2023Offer documentSEC
6-K · Report of a foreign issuerAug 14, 2023Current reportSEC
6-K · Report of a foreign issuerAug 8, 2023Current reportSEC
4 · Change in ownershipJul 5, 2023Insider tradeSEC
6-K · Report of a foreign issuerJul 3, 2023Current reportSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 16, 2023Insider tradeSEC
8-K · Current reportJun 16, 2023Management or board changeSEC
3 · Initial statement of ownershipJun 5, 2023Insider tradeSEC
8-K · Current reportJun 5, 2023Management or board changeSEC
RW · Request to withdraw a registrationJun 2, 2023Other filingsSEC
S-1/A · Registration statement, amendedMay 19, 2023Offer documentSEC
8-K · Current reportMay 11, 2023ResultsSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
4 · Change in ownershipMar 23, 2023Insider tradeSEC
4 · Change in ownershipMar 23, 2023Insider tradeSEC
4 · Change in ownershipMar 23, 2023Insider tradeSEC
4 · Change in ownershipMar 23, 2023Insider tradeSEC
S-1/A · Registration statement, amendedMar 22, 2023Offer documentSEC
S-1/A · Registration statement, amendedMar 21, 2023Offer documentSEC
ARS · Annual report to shareholdersMar 21, 2023Annual reportSEC
10-K · Annual reportMar 20, 2023Annual reportSEC
S-1/A · Registration statement, amendedFeb 22, 2023Offer documentSEC
8-K · Current reportFeb 21, 2023Current reportSEC
S-1/A · Registration statement, amendedFeb 21, 2023Offer documentSEC
8-K · Current reportFeb 21, 2023ResultsSEC
S-1 · Registration statementJan 13, 2023Offer documentSEC
8-K · Current reportJan 11, 2023Current reportSEC
4 · Change in ownershipJan 5, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJan 5, 2023Big-stake noticeSEC
4 · Change in ownershipJan 5, 2023Insider tradeSEC
8-K · Current reportJan 3, 2023Current reportSEC
8-K/A · Current report, amendedNov 29, 2022Current reportSEC
4 · Change in ownershipNov 18, 2022Insider tradeSEC
4 · Change in ownershipNov 17, 2022Insider tradeSEC
SC 13D/A · Big-stake notice, amendedNov 17, 2022Big-stake noticeSEC
8-K · Current reportNov 16, 2022Current reportSEC
3 · Initial statement of ownershipNov 15, 2022Insider tradeSEC
8-K · Current reportNov 14, 2022Management or board changeSEC
10-Q · Quarterly reportNov 10, 2022Quarterly reportSEC
S-8 · Registration statement for employee plansAug 15, 2022Offer documentSEC
10-Q · Quarterly reportAug 12, 2022Quarterly reportSEC
8-K · Current reportAug 12, 2022ResultsSEC
3 · Initial statement of ownershipJun 21, 2022Insider tradeSEC
8-K · Current reportJun 21, 2022Current reportSEC
4 · Change in ownershipJun 21, 2022Insider tradeSEC
8-K · Current reportJun 8, 2022Meeting outcomeSEC
8-K · Current reportJun 1, 2022Management or board changeSEC
DEFA14A · Additional proxy materialMay 31, 2022Meeting noticeSEC
4 · Change in ownershipMay 25, 2022Insider tradeSEC
4 · Change in ownershipMay 19, 2022Insider tradeSEC
10-Q · Quarterly reportMay 12, 2022Quarterly reportSEC
8-K · Current reportMay 12, 2022ResultsSEC
DEF 14A · Proxy statementApr 28, 2022Meeting noticeSEC
424B5 · ProspectusApr 25, 2022Offer documentSEC
10-K · Annual reportMar 30, 2022Annual reportSEC
4 · Change in ownershipMar 21, 2022Insider tradeSEC
4 · Change in ownershipMar 21, 2022Insider tradeSEC
4 · Change in ownershipMar 15, 2022Insider tradeSEC
4 · Change in ownershipMar 15, 2022Insider tradeSEC
4 · Change in ownershipMar 14, 2022Insider tradeSEC
4 · Change in ownershipMar 9, 2022Insider tradeSEC
4 · Change in ownershipMar 9, 2022Insider tradeSEC
4 · Change in ownershipMar 9, 2022Insider tradeSEC
4 · Change in ownershipMar 9, 2022Insider tradeSEC
4 · Change in ownershipMar 9, 2022Insider tradeSEC
8-K · Current reportMar 9, 2022ResultsSEC
8-K · Current reportFeb 11, 2022Meeting outcomeSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2022Big-stake noticeSEC
SC 13D · Big-stake noticeJan 20, 2022Big-stake noticeSEC
DEF 14A · Proxy statementJan 5, 2022Meeting noticeSEC
PRE 14A · Preliminary proxy statementDec 23, 2021Meeting noticeSEC
8-K · Current reportDec 16, 2021Management or board changeSEC
4 · Change in ownershipDec 8, 2021Insider tradeSEC
8-K · Current reportDec 3, 2021Management or board changeSEC
8-K/A · Current report, amendedNov 12, 2021Management or board changeSEC
10-Q · Quarterly reportNov 12, 2021Quarterly reportSEC
8-K · Current reportNov 12, 2021ResultsSEC
3 · Initial statement of ownershipNov 12, 2021Insider tradeSEC
8-K · Current reportNov 10, 2021Current reportSEC
8-K · Current reportNov 8, 2021Management or board changeSEC
3 · Initial statement of ownershipNov 4, 2021Insider tradeSEC
8-K · Current reportNov 3, 2021Current reportSEC
8-K · Current reportOct 26, 2021Meeting outcomeSEC
8-K · Current reportOct 25, 2021Current reportSEC
DEF 14A · Proxy statementSep 17, 2021Meeting noticeSEC
S-8 · Registration statement for employee plansSep 13, 2021Offer documentSEC
PRE 14A · Preliminary proxy statementSep 3, 2021Meeting noticeSEC
8-K · Current reportSep 2, 2021Management or board changeSEC
10-Q · Quarterly reportAug 13, 2021Quarterly reportSEC
8-K · Current reportAug 13, 2021ResultsSEC
8-K · Current reportJul 22, 2021Meeting outcomeSEC
DEF 14A · Proxy statementJun 14, 2021Meeting noticeSEC
PRE 14A · Preliminary proxy statementJun 1, 2021Meeting noticeSEC
EFFECT · Notice that a registration is effectiveMay 18, 2021Other filingsSEC
8-K · Current reportMay 13, 2021ResultsSEC
10-Q · Quarterly reportMay 13, 2021Quarterly reportSEC
CORRESP · Letter to the SECMay 12, 2021Other filingsSEC
4 · Change in ownershipMay 10, 2021Insider tradeSEC
UPLOAD · Letter from the SECMay 5, 2021Other filingsSEC
S-3 · Registration statementApr 30, 2021Offer documentSEC
424B3 · ProspectusApr 29, 2021Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 29, 2021Other filingsSEC
CORRESP · Letter to the SECApr 26, 2021Other filingsSEC
UPLOAD · Letter from the SECApr 23, 2021Other filingsSEC
4 · Change in ownershipApr 21, 2021Insider tradeSEC
4 · Change in ownershipApr 21, 2021Insider tradeSEC
4 · Change in ownershipApr 21, 2021Insider tradeSEC
4 · Change in ownershipApr 21, 2021Insider tradeSEC
4 · Change in ownershipApr 21, 2021Insider tradeSEC
4 · Change in ownershipApr 21, 2021Insider tradeSEC

This page holds 200 of 369 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Chemomab Therapeutics Ltd.’s releases · as of Nov 3, 2026

Common shares
8,048,615
Fully diluted
8,048,615

Fully diluted

LineShares
Common shares8,048,615

Share count over time

CountShares
Nov 22, 20268,048,615

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Citadel110K1.4%US$131KSep 30, 2026
Kestra Private Wealth Services, LLC77,1530.96%US$91,812Sep 30, 2026
Ikarian Capital, LLC51,7930.64%US$61,633Sep 30, 2026
Rhumbline Advisers30,0700.37%US$35,780Sep 30, 2026
Susquehanna24,4080.30%US$29,046Sep 30, 2026
Philadelphia Investment Partners, LLC22,5660.28%US$26,854Sep 30, 2026
Jane Street19,6370.24%US$23,368Sep 30, 2026
StoneX Group Inc.18,6200.23%US$29,807Sep 30, 2026
Two Sigma13,6690.17%US$16,266Sep 30, 2026
SmartHarvest Portfolios, LLC13,0310.16%US$15,507Sep 30, 2026
All 16 holders
HolderSharesOf the companyValueAs of
Renaissance Technologies10,3280.13%US$12,290Sep 30, 2026
BNP Paribas3,3000.04%US$3,927Sep 30, 2026
Morgan Stanley1,6000.02%US$1,904Sep 30, 2026
Nuveen235<0.01%US$378Sep 30, 2026
SBI Securities Co., Ltd.30<0.01%US$36Sep 30, 2026
Caitong International Asset Management Co., Ltd17<0.01%US$20Sep 30, 2026

Big stakes

StakeStakeSharesDateFiling
Scipher Medicine Corp10.40%74.6MNov 3, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Stephen J DiPalma
Other companies: Inozyme Pharma Inc (Interim CFO · May 17, 2021 – May 17, 2021 · Past); Solid Biosciences Inc. (Interim CFO · Jan 29, 2021 – Jan 29, 2021 · Past); Generation Bio Co (See Remarks · Jun 11, 2020 – Jun 11, 2020 · Past); Spero Therapeutics, Inc. (See Remarks · Nov 8, 2019 – Jul 15, 2023 · Past); Interleukin Genetics Inc (Interim CFO · Jul 29, 2016 – Jul 29, 2016 · Past)
Chief Financial Officer · May 1, 2020 – May 1, 2020 · Past
Jill Quigley
Other companies: Terns Pharmaceuticals, Inc. (Director · Since at least Feb 4, 2021); Passage Bio, Inc. (Chief Operating Officer · Feb 27, 2020 – Dec 8, 2021 · Past)
Board Director · Since at least Jun 16, 2022
Alan Moses
Other companies: BiomX Inc. (Director · Oct 2, 2020 – Apr 14, 2025 · Past)
Board Director · Since at least Mar 16, 2021
Isaac T. Kohlberg
Other companies: Acacia Research Corporation (Director · Since at least May 6, 2019)
Director · Jan 1, 2020 – Jan 1, 2020 · Past
Reginald L Hardy
Other companies: Brickell Biotech Inc (CHAIRMAN OF THE BOARD, Director · Aug 31, 2019 – May 17, 2022 · Past)
Director · Jan 1, 2020 – Jan 1, 2020 · Past
Adi MorCo-Founder, Chief Executive Officer and Chief Scientific Officer · Since at least Nov 5, 2026
Arnon AharonChief Medical Officer · Mar 16, 2021 – Mar 16, 2021 · Past
Barbara LindheimConsulting Vice President, Strategic Communications, Investor & Public Relations · Since at least Nov 2, 2026
Claude NicaiseBoard Director · Since at least Nov 5, 2026
David WeinerInterim Chief Medical Officer · Since at least Nov 4, 2026
All 21 people
PersonSeat
Donald MarvinExecutive VP, CFO & COO · Nov 8, 2021 – Mar 16, 2022 · Past
Gwen MelincoffBoard Director · Since at least Nov 5, 2026
Jack LawlerChief Development Officer · Since at least Nov 4, 2026
Neil CohenBoard Director · Since at least Apr 23, 2020
Nissim DarvishDirector · Since at least Mar 16, 2021
Revital ArichaVice President, Translational Science · Since at least Nov 4, 2026
Ron KnickerbockerSee Remarks · Jan 1, 2020 – Jan 1, 2020 · Past
Salar RoshanHead of Business Development · Jan 1, 2020 – Jan 1, 2020 · Past
Sigal FatalChief Financial Officer · Since at least Mar 18, 2026
Sigal FattalChief Financial Officer · Since at least Nov 4, 2026
Stanislav PolovetsDirector · Apr 23, 2020 – Apr 23, 2020 · Past

Open People

Log in to ask 6ix AI your own questions about Chemomab Therapeutics Ltd.